Top

Strahlentherapie und Onkologie

Published in:

02-02-2023 | Radiotherapy | Original Article

Chemoradiotherapy for untreated Masaoka–Koga stage IVB thymic carcinoma: a single-center retrospective study

Authors: Jia-nan Jin, Yue Hao, Wen-xian Wang, Shi-yan Wu, Peng Yue, Dr. Zheng-bo Song

Published in: Strahlentherapie und Onkologie | Issue 3/2023

Abstract

Background

Thymic carcinoma (TC) is a rare type of a malignant tumor. The optimal treatment for Masaoka–Koga stage IVB TC patients is controversial due to the rarity of the disease. Chemotherapy is still the preferred option, but the outcomes are unsatisfactory. Whether radiotherapy combined with chemotherapy could improve prognosis remains unclear.

Methods

Untreated stage IVB TC patients who have received first-line chemotherapy were included in the present study. The patients who have undergone surgery were excluded. The primary outcomes were objective response rate (ORR) and progression-free survival (PFS).

Results

Sixty-seven patients were included in the study. A total of 31 patients received chemoradiotherapy (ChemoRT cohort), and the remaining 36 patients only received chemotherapy (Chemo cohort). The median follow-up period was 40.3 months. The ORR for the ChemoRT and Chemo cohorts was 61.3 and 27.8%, respectively (P = 0.006). Furthermore, PFS (P = 0.003) and OS (P = 0.046) were significantly superior in the ChemoRT cohort. Radiotherapy maintained a significant favorable effect on PFS in multivariate analysis (P = 0.014), but the effect on OS was insignificant (P = 0.249). There was no advantage in PFS (P = 0.302) in the ChemoRT cohort in patients who received < 4 cycles of chemotherapy. In contrast, radiotherapy significantly improved PFS (P = 0.005) in patients who received ≥ 4 cycles of chemotherapy.

Conclusions

Chemoradiotherapy used as the first-line treatment improved ORR and PFS in Masaoka–Koga stage IVB TC patients. Patients receiving more cycles of chemotherapy may have a better chance to benefit from chemoradiotherapy.

Available only for authorised users

de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ (2008) Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 44(1):123–130. https://doi.org/10.1016/j.ejca.2007.11.004CrossRefPubMed

Shin DW, Cho JH, Ha J, Jung KW (2022) Trends in incidence and survival of patients with thymic epithelial tumor in a high-incidence asian country: analysis of the Korean central cancer registry 1999 to 2017. J Thorac Oncol 17(6):827–837. https://doi.org/10.1016/j.jtho.2022.02.001CrossRefPubMed

Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48(11):2485–2492. https://doi.org/10.1002/1097-0142(19811201)48:11〈2485::aid-cncr2820481123〉3.0.co;2‑rCrossRefPubMed

Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, Shimosato Y (1994) A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 44(5):359–367. https://doi.org/10.1111/j.1440-1827.1994.tb02936.xCrossRefPubMed

Modh A, Rimner A, Allen PK, Greenfield B, Marom EM, Rice D, Huang J, Rosenzweig KE, Komaki R, Gomez DR (2016) Treatment modalities and outcomes in patients with advanced invasive thymoma or thymic carcinoma: a retrospective multicenter study. Am J Clin Oncol 39(2):120–125. https://doi.org/10.1097/COC.0000000000000024CrossRefPubMedPubMedCentral

Cardillo G, Carleo F, Giunti R, Lopergolo MG, Salvadori L, De Massimi AR, Petrella L, Martelli M (2010) Predictors of survival in patients with locally advanced thymoma and thymic carcinoma (Masaoka stages III and IVa). Eur J Cardiothorac Surg 37(4):819–823. https://doi.org/10.1016/j.ejcts.2009.11.001CrossRefPubMed

Zhai Y, Chen D, Gao Y, Hui Z, Xue L, Zhou Z, Luo Y, Xiao Z, Feng Q (2021) Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. Tumori 107(5):407–415. https://doi.org/10.1177/0300891620967980CrossRefPubMed

Yang X, Zhuo M, Shi A, Yang S, Wang Z, Wu M, An T, Wang Y, Li J, Zhong J, Chen H, Jia B, Dong Z, Zhao J (2019) Optimal first-line treatment for advanced thymic carcinoma. Thorac Cancer 10(11):2081–2087. https://doi.org/10.1111/1759-7714.13181CrossRefPubMedPubMedCentral

Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Suzuki S, Fujii Y (2008) Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 3(3):265–269. https://doi.org/10.1097/JTO.0b013e3181653c71CrossRefPubMed

10.

Ye C, Bao M, Li H, Liu X, Jiang G, Wang W (2020) Surgery in Masaoka stage IV thymic carcinoma: a propensity-matched study based on the SEER database. J Thorac Dis 12(3):659–671. https://doi.org/10.21037/jtd.2019.12.111CrossRefPubMedPubMedCentral

11.

Yang Y, Fan XW, Wang HB, Xu Y, Li DD, Wu KL (2017) Stage IVb thymic carcinoma: patients with lymph node metastases have better prognoses than those with hematogenous metastases. BMC Cancer 17(1):217. https://doi.org/10.1186/s12885-017-3228-2CrossRefPubMedPubMedCentral

12.

Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ Sr (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29(15):2060–2065. https://doi.org/10.1200/JCO.2010.32.9607CrossRefPubMedPubMedCentral

13.

Nonaka T, Tamaki Y, Higuchi K, Katoh H, Nakahashi M, Horikoshi H, Takahashi K, Minato K, Sugihara S, Kojima M (2004) The role of radiotherapy for thymic carcinoma. Jpn J Clin Oncol 34(12):722–726. https://doi.org/10.1093/jjco/hyh141CrossRefPubMed

14.

Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL, Mukai K, Orazi A, Ströbel P (2015) The 2015 World Health Organization classification of tumors of the thymus: continuity and changes. J Thorac Oncol 10(10):1383–1395. https://doi.org/10.1097/JTO.0000000000000654CrossRefPubMedPubMedCentral

15.

Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346. https://doi.org/10.1016/0360-3016(95)00060-CCrossRefPubMed

16.

Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K, Kogure Y, Shimizu J, Kimura T, Fukuoka J, Iwamoto Y, Sasaki H, Takeda K, Seto T, Ichinose Y, Nakagawa K, Nakanishi Y (2015) A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol 26(2):363–368. https://doi.org/10.1093/annonc/mdu541CrossRefPubMed

17.

Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, Kaira K, Ono A, Shukuya T, Tamiya A, Endo M, Yamamoto N (2010) Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 67(2):194–197. https://doi.org/10.1016/j.lungcan.2009.03.031CrossRefPubMed

18.

Komaki R, Gomez DR (2014) Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive. Front Oncol 10(3):330. https://doi.org/10.3389/fonc.2013.00330CrossRef

19.

Wang J, Ji Z, Wang X, Liang J, Hui Z, Lv J, Zhou Z, Yin W, Wang L (2016) Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer. Thorac Cancer 7(2):182–189. https://doi.org/10.1111/1759-7714.12305CrossRefPubMed

20.

Chen YY, Huang CH, Tang Y, Eng HL (2004) Concurrent chemoradiotherapy for unresectable thymic carcinoma. Chang Gung Med J 27(7):515–522PubMed

21.

Chu RF, Hussien A, Li QK, Wang J, Friedes C, Ferro A, Hales RK, Battafarano R, Ettinger DS, Voong KR (2020) Radiologic response of chemotherapy alone versus radiation and chemotherapy in the treatment of locally-advanced or advanced thymic epithelial tumors. Thorac Cancer 11(10):2924–2931. https://doi.org/10.1111/1759-7714.13635CrossRefPubMedPubMedCentral

22.

Fan XW, Yang Y, Wang HB, Xu Y, Kang M, Xie LY, Li L, Fang WT, Zhao KL, Chen HQ, Xiang JQ, Ung YC, Wong CS, Jiang GL, Wu KL (2020) Intensity modulated radiation therapy plus etoposide/cisplatin for patients with limited advanced unresectable thymic epithelial tumors: A prospective phase 2 study. Int J Radiat Oncol Biol Phys 107(1):98–105. https://doi.org/10.1016/j.ijrobp.2019.12.045CrossRefPubMed

23.

Zheng L, Wang Y, Xu Z, Yang Q, Zhu G, Liao XY, Chen X, Zhu B, Duan Y, Sun J (2019) Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist 24(8):1031–e612. https://doi.org/10.1634/theoncologist.2019-0285CrossRefPubMedPubMedCentral

24.

Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G (2015) Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 16(2):177–186. https://doi.org/10.1016/S1470-2045(14)71181-7CrossRefPubMedPubMedCentral

25.

Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Nagasaka Y, Kawasaki M, Yamada T, Machida R, Kuchiba A, Ohe Y, Yamamoto N (2020) Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 21(6):843–850. https://doi.org/10.1016/S1470-2045(20)30162-5CrossRefPubMed

26.

Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN (2018) Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 19(3):347–355. https://doi.org/10.1016/S1470-2045(18)30062-7CrossRefPubMed

27.

Frey B, Rubner Y, Kulzer L, Werthmöller N, Weiss EM, Fietkau R, Gaipl US (2014) Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 63(1):29–36. https://doi.org/10.1007/s00262-013-1474-yCrossRefPubMed

28.

Chiappetta M, Lococo F, Pogliani L, Sperduti I, Tabacco D, Bria E, D’Argento E, Massaccesi M, Boldrini L, Meacci E, Porziella V, Nachira D, Congedo MT, Margaritora S (2021) Masaoka-Koga and TNM staging system in thymic epithelial tumors: Prognostic comparison and the role of the number of involved structures. Cancers 13(21):5254. https://doi.org/10.3390/cancers13215254CrossRefPubMedPubMedCentral

29.

Weksler B, Holden A, Sullivan JL (2015) Impact of positive nodal metastases in patients with thymic carcinoma and thymic neuroendocrine tumors. J Thorac Oncol 10(11):1642–1647. https://doi.org/10.1097/JTO.0000000000000660CrossRefPubMed

Title: Chemoradiotherapy for untreated Masaoka–Koga stage IVB thymic carcinoma: a single-center retrospective study
Authors: Jia-nan Jin
Yue Hao
Wen-xian Wang
Shi-yan Wu
Peng Yue
Dr. Zheng-bo Song
Publication date: 02-02-2023
Publisher: Springer Berlin Heidelberg
Keywords: Radiotherapy
Cytostatic Therapy
Published in: Strahlentherapie und Onkologie / Issue 3/2023
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-022-02042-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Chemoradiotherapy for untreated Masaoka–Koga stage IVB thymic carcinoma: a single-center retrospective study

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2023

Verlängerung des Gesamtüberlebens durch die Impfung von autologen tumorlysatbeladenen dendritischen Zellen (DCVax-L) bei Patienten mit neu diagnostiziertem und rezidivierendem Glioblastom

Testicular germ cell tumour arising 15 years after radiotherapy with 18 Gy for germ cell neoplasia in situ

Palliative care on the radiation oncology ward—improvements in clinical care through interdisciplinary ward rounds

Physical and nonphysical effects of weekly music therapy intervention on the condition of radiooncology patients

Traditional risk factors and nodal yield—still relevant with high-quality risk-adapted adjuvant treatment for locally advanced head and neck cancer?

Clinical outcomes and factors involved in the local control of proton beam therapy for oligometastatic liver tumors in patients with colorectal cancer

Testicular germ cell tumour arising 15 years after radiotherapy with 18 Gy for germ cell neoplasia in situ